Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease
The DOI matches its Crossref record; 40 of the 41 references it cites were found in a registry or an index.
Abstract
Gene dosage of the apolipoprotein E (APOE) epsilon 4 allele is a major risk factor for familial Alzheimer disease (AD) of late onset (after age 60). Here we studied a large series of 115 AD case subjects and 243 controls as well as 150 affected and 197 unaffected members of 66 AD families. Our data demonstrate a protective effect of the epsilon 2 allele, in addition to the dose effect of the epsilon 4 allele in sporadic AD. Although a substantial proportion (65%) of AD is attributable to the presence of epsilon 4 alleles, risk of AD is lowest in subjects with the epsilon 2/epsilon 3 genotype, with an additional 23% of AD attributable to the absence of an epsilon 2 allele. The opposite actions of the epsilon 2 and epsilon 4 alleles further support the direct involvement of APOE in the pathogenesis of AD.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Common variants of the apolipoprotein E gene (APOE) influence the risk of Alzheimer’s disease: APOE4 is linked to high risk, APOE3 is considered to confer a neutral risk, and APOE2 is associated with relative protection.2–5”
From APOE3 Christchurch Heterozygosity and Autosomal Dominant Alzheimer’s Disease (2024) · cites this paper as [5]
Experimental — accuracy not yet measuredIn the citing paper
“APOE, the major susceptibility gene for late-onset AD, has three common alleles (APOE2, 3, and 4).”
From Resistance to autosomal dominant Alzheimer’s disease in an APOE3 Christchurch homozygote: a case report (2019) · cites this paper as [10]
In the citing paper
“Compared to the most common APOE3/3 genotype, which is considered neutral with regard to AD risk, APOE2 is associated with a lower AD risk and older age at dementia onset, and each additional copy of APOE4 is associated with a higher risk and younger age at onset.10”
From Resistance to autosomal dominant Alzheimer’s disease in an APOE3 Christchurch homozygote: a case report (2019) · cites this paper as [10]
In the citing paper
“Apolipoprotein E (APOE), the major susceptibility gene for late-onset Alzheimer’s disease (AD), has three common alleles (APOE2, 3, and 4), giving rise to six genotypes (APOE2/2, 2/3, 3/3, 2/4, 3/4, and 4/4).”
From Exceptionally low likelihood of Alzheimer’s dementia in APOE2 homozygotes from a 5,000-person neuropathological study (2020) · cites this paper as [2]
In the citing paper
“while the presence of one or two copies of the APOE2 allele is associated with a lower risk of Alzheimer’s dementia and an older mean age at dementia onset1–4.”
From Exceptionally low likelihood of Alzheimer’s dementia in APOE2 homozygotes from a 5,000-person neuropathological study (2020) · cites this paper as [2]
38 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915
Corder, E. H., Saunders, A. M., Strittmatter, W. J., Schmechel, D. E., Gaskell, P. C., Small, G. W., Roses, A. D., Haines, J. L., & Pericak-Vance, M. A. (1993) · Science · doi:10.1126/science.8346443 · Cited by 9,429
Self-citationGoate, A., Chartier-Harlin, M.-C., Mullan, M., Brown, J., Crawford, F., Fidani, L., Giuffra, L., Haynes, A., Irving, N., James, L., et al. (1991) · Nature · doi:10.1038/349704a0 · Cited by 4,659
Self-citationStrittmatter, W. J., Saunders, A. M., Schmechel, D., Pericak-Vance, M., Enghild, J., Salvesen, G. S., & Roses, A. D. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.5.1977 · Cited by 4,268
Self-citationApolipoprotein E: Cholesterol Transport Protein with Expanding Role in Cell Biology
Mahley, R. W. (1988) · Science · doi:10.1126/science.3283935 · Cited by 4,028
Association of apolipoprotein E allele ϵ4 with late‐onset familial and sporadic Alzheimer's disease
Saunders, A. M., Strittmatter, W. J., Schmechel, D., St. George-Hyslop, P. H., Pericak-Vance, M. A., Joo, S. H., Rosi, B. L., Gusella, J. F., Crapper-MacLachlan, D. R., Alberts, M. J., et al. (1993) · Neurology · doi:10.1212/wnl.43.8.1467 · Cited by 3,786
Self-citationDiagnosis of Alzheimer's Disease
Khachaturian, Z. S. (1985) · Archives of Neurology · doi:10.1001/archneur.1985.04060100083029 · Cited by 2,499
Schmechel, D. E., Saunders, A. M., Strittmatter, W. J., Crain, B. J., Hulette, C. M., Joo, S. H., Pericak-Vance, M. A., Goldgaber, D., & Roses, A. D. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.20.9649 · Cited by 1,525
Self-citationStrittmatter, W. J., Weisgraber, K. H., Huang, D. Y., Dong, L. M., Salvesen, G. S., Pericak-Vance, M., Schmechel, D., Saunders, A. M., Goldgaber, D., & Roses, A. D. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.17.8098 · Cited by 1,363
Self-citationThe Genetic Defect Causing Familial Alzheimer's Disease Maps on Chromosome 21
St George-Hyslop, P. H., Tanzi, R. E., Polinsky, R. J., Haines, J. L., Nee, L., Watkins, P. C., Myers, R. H., Feldman, R. G., Pollen, D., Drachman, D., et al. (1987) · Science · doi:10.1126/science.2880399 · Cited by 1,163
Self-citation
Research works printed but not linked: 2
- Cornoni-Huntley, J., Blazer, D.G., Service, C. & Farmer, M.E. in Established population for epidemiologic studies of the elderly. Volume II (eds Cornoni-Huntley, J. et al.) 1–7 (NIH publication 90–495, Bethesda, 1990).
- Rothman, K.J. Modern Epidemiology. 38–39, 76 (Little, Brown & Company, Boston, 1986).
Cited by
Items 1,001–1,030 of 1,030
Golden, L. R., Siano, D. S., Stephens, I. O., MacLean, S. M., Saito, K., Nolt, G. L., Funnell, J. L., Pallerla, A. V., Lee, S., Smith, C., et al. (2025) · Nature Neuroscience · doi:10.1038/s41593-025-02094-y · Cited by 31
Venzi, M., Tóth, M., Häggkvist, J., Bogstedt, A., Rachalski, A., Mattsson, A., Frumento, P., & Farde, L. (2017) · Journal of Alzheimer's Disease Reports · doi:10.3233/adr-170006 · Cited by 18
“In clinical neuroscience research a strong interest for ApoE has arisen from the finding that the 4 allele is an established risk factor for Alzheimer’s disease (AD) [7] while the 2 allele, at least in some human samples, appears to be protective against AD in comparison to 3 [8, 9].”
BackgroundSim, K.-Y., Park, S.-H., Choi, K. Y., Park, J. E., Lee, J. S., Kim, B. C., Gwak, J., Song, W. K., Lee, K. H., & Park, S.-G. (2019) · Scientific Reports · doi:10.1038/s41598-019-40976-x · Cited by 18
Padgett, C. R., Summers, M. J., Vickers, J. C., McCormack, G. H., & Skilbeck, C. E. (2016) · Journal of Clinical and Experimental Neuropsychology · doi:10.1080/13803395.2015.1137557 · Cited by 17
“This may be problematic not only because of the evidence that APOEe2 confers a protective effect against neurological impairment, but also because APOEe2 is believed to be dominant over the other two alleles (Corder et al., 1994; Suri et al., 2013).”
BackgroundShafer, A. T., Beason-Held, L., An, Y., Williams, O. A., Huo, Y., Landman, B. A., Caffo, B. S., & Resnick, S. M. (2021) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2021.03.013 · Cited by 16
Biundo, F., Ishiwari, K., Del Prete, D., & D’Adamio, L. (2015) · Neurobiology of Learning and Memory · doi:10.1016/j.nlm.2015.10.009 · Cited by 13
“By contrast, the ApoE2 allele has been shown to have protective effects on AD (Corder et al., 1994; Panza et al., 2000; West, Rebeck, & Hyman, 1994), while the ApoE3 allele, which is the most predominant isoform accounting almost 80% of alleles in general population, is considered to be neutral…”
Membership in genetic groups predicts Alzheimer disease.
Corder, E. H., Huang, R., Cathcart, H. M., Lanham, I. S., Parker, G. R., Cheng, D., Smith, S., & Poduslo, S. E. (2006) · Rejuvenation Research · doi:10.1089/rej.2006.9.89 · Cited by 13
Self-citationKAPLITT, M., GOURAS, G. K., MAKIMURA, H., JOVANOVIC, J., SWEENEY, D., GREENGARD, P., RELKIN, N. R., & GANDY, S. (1996) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1996.tb32597.x · Cited by 12
A framework for modeling epistatic interaction
Blumenthal, D. B., Baumbach, J., Hoffmann, M., Kacprowski, T., & List, M. (2021) · Bioinformatics · doi:10.1093/bioinformatics/btaa990 · Cited by 10
Takacs, C. N., Andreo, U., Belote, R. L., Pulupa, J., Scull, M. A., Gleason, C. E., Rice, C. M., & Simon, S. M. (2017) · Traffic · doi:10.1111/tra.12467 · Cited by 10
Miyoshi, E., Morabito, S., & Swarup, V. (2021) · Neurobiology of Disease · doi:10.1016/j.nbd.2021.105530 · Cited by 7
APOE genotype-dependent differences in human astrocytic energy metabolism
Budny, V., Bodenmann, C., Zürcher, K. J., Krüger, M., de Leeuw, S. M., Weber, R. Z., Rust, R., Ravotto, L., Ruminot, I., Barros, L. F., et al. (2025) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2025.1603657 · Cited by 6
Microglia-derived APOE2 improves remyelination even in the presence of endogenous APOE4
Nolt, G. L., Golden, L. R., Thorpe, S. P., Funnell, J. L., Stephens, I. O., Hernandez, G., MacLean, S. M., Lucido, C. C., Brock, C. R., Pallerla, A. V., et al. (2025) · Journal of Neuroinflammation · doi:10.1186/s12974-025-03639-5 · Cited by 5
“Finally, we chose to investigate the effects of microglial E2 expression because of the protective effects of E2 in AD and MS [17, 19, 21, 22, 50].”
Molecular Mechanisms of the R61T Mutation in Apolipoprotein E4: A Dynamic Rescue
Williams, B., Convertino, M., Das, J., & Dokholyan, N. V. (2017) · Biophysical Journal · doi:10.1016/j.bpj.2017.08.026 · Cited by 5
Protective ApoE variants support neuronal function by extracting peroxidated lipids
Ralhan, I., Do, A. D., Bae, J.-Y., Feringa, F. M., Cai, W., Chang, J., Chik, K., Lee, N. Y., Gerry, C., van der Kant, R., et al. (2025) · bioRxiv · doi:10.1101/2025.03.05.641722 · Cited by 4
APOE Genotype Influences Postprandial Blood Pressure After High fat Feeding in Older Adults
Stewart, K. C., Subramanian, D., Neal, U. J., & Hanson, A. J. (2019) · The Journal of nutrition, health and aging · doi:10.1007/s12603-019-1167-0 · Cited by 3
ApoE expression across the CNS: Who, What, Where, When, and How (much)?
Nolt, G. L., Lucido, C. C., Smith, L. M., & Johnson, L. A. (2026) · Molecular Neurodegeneration Advances · doi:10.1186/s44477-026-00028-x · Cited by 2
Andrieieva, D., Falltrick, I., Chiang, C.-Y., Beaumont, B., Guen, Y. L., Liu, C., Pergolesi, S., Ma, C.-T., Jackson, M. R., Hyman, B. T., et al. (2026) · doi:10.64898/2026.05.09.26352797 · Cited by 2
Hernandez Arriaza, R., Reil, D., Fatuzzo, N., Fu, M., Dai, Y., Fernandez Martinez, D., Jiang, H., Holtzman, D. M., Greicius, M. D., & Khosla, C. (2025) · Biochemistry · doi:10.1021/acs.biochem.5c00503 · Cited by 2
Diagnostic criteria for primary progressive mutiple sclerosis: a position paper.
(2000) · Pure Amsterdam UMC · doi:10.1002/1531-8249(200006)47:6 · Cited by 2
E280A PS-1 mutation causes Alzheimer's disease but age of onset is not modified by ApoE alleles
Lendon, C. L., Martinez, A., Behrens, I. M., Kosik, K. S., Madrigal, L., Norton, J., Neuman, R., Myers, A., Busfield, F., Wragg, M., et al. (1997) · Human Mutation · doi:10.1002/(sici)1098-1004(1997)10:3
Berlau, D. J., Kahle-Wrobleski, K., Head, E., Goodus, M., Kim, R., & Kawas, C. (2007) · Archives of Neurology · doi:10.1001/archneur.64.8.1193
“2007;64(8):1193-1196 I N THE LAST DECADE, MANY STUD-ies (for a review, see Laws et al1)haveexaminedtheroleof theapo-lipoproteinE(APOE)genotype inthedevelopmentofAlzheimerdisease (AD) and neuropathologic findings in AD.”
InfluentialChen, K., Chen, Y., Ren, Y., Wang, Z., Huang, Y., Pan, M., Li, Z., Casey, M. C., Qiao, W., Shi, J., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-78407-x
Jackson, R. J., Dierksmeier, S., Nishtar, M., Meltzer, J., Balduin, F., Beaumont, B., Fan, Z., Sergienko, E., Olson, S., Jackson, M. R., et al. (2026) · doi:10.64898/2026.06.09.730809
“Conversely, the 2 allele confers protection against AD 7,8 .”
Gonzalez-Salvador (1999) · doi:10.1002/(sici)1099-1166(199909)14:9
Nolt, G. L., MacLean, S. M., Golden, L. R., Thorpe, S. P., Stephens, I. O., Funnell, J. L., Brock, C. R., Lucido, C. C., Smith, L., Hernandez, G., et al. (2027) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2026.08.005
Strickland, M. R., & Holtzman, D. M. (2026) · Molecular Neurodegeneration · doi:10.1186/s13024-026-00970-0
“In contrast to ε4, the presence of the ε2 allele is protective relative to individuals who are ε3/ε3 [4, 6].”
Capila, I., & Linhardt, R. J. (2002) · Angewandte Chemie International Edition · doi:10.1002/1521-3773(20020201)41:3<390::aid-anie390>3.0.co;2-b
Abbeduto (2004) · doi:10.1352/0895-8017(2004)109
Cole (2000) · doi:10.1002/1097-0029(20000815)50:4<316::aid-jemt11>3.0.co;2-e
“Whereas ApoE had been previously discovered in A! deposits (Namba et al., 1992), the identification of the APOE4 allele as a genetic risk factor for AD and the APOE2 allele as protective ( Corder et al.,1994; Saunders et al., 1993) demonstrated some important role for ApoE in the pathogenesis of AD (Hyman, 1997; Mahle…”
Background
Metadata
- Authors
- Corder, E. H., Saunders, A. M., Risch, N. J., Strittmatter, W. J., Schmechel, D. E., Gaskell, P. C., Rimmler, J. B., Locke, P. A., Conneally, P. M., Schmader, K. E., Small, G. W., Roses, A. D., Haines, J. L., & Pericak-Vance, M. A.
- Affiliations
- Duke University (US)
- Yale University (US)
- Massachusetts General Hospital (US)
- Indiana University School of Medicine (US)
- University of California, Los Angeles (US)
- Venue
- Nature Genetics
- Published
- 1994-06
- Volume
- 7
- Issue
- 2
- Pages
- 180-184
- ISSN
- 1061-4036 (ISSN-L)
- 1546-1718
- OpenAlex
- W2090271811
- Cited by
- 1,920
- References
- 41
- Citations by year
- 2026: 45 · 2025: 77 · 2024: 78 · 2023: 59 · 2022: 66 · 2021: 76 · 2020: 76 · 2019: 58 · 2018: 62 · 2017: 58 · 2016: 75 · 2015: 55 · 2014: 63 · 2013: 68 · 2012: 66
- FWCI
- 54.52
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Genetics (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute on Aging (NIA AG05128, U24AG021886)
- National Institute of Neurological Disorders and Stroke (P01NS026630, NINDS NS26630, NINDS NS531153)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Associations and Epidemiology
- Keywords
- apolipoprotein E, APOE ε4, late-onset Alzheimer's disease, familial Alzheimer's disease, gene dosage, protective effect, sporadic Alzheimer's disease, genetic risk factors, APOE genotype
- MeSH terms
- Aged, Alleles, Alzheimer Disease, Apolipoproteins E, Female, Gene Frequency, Genotype, Humans, Male, Middle Aged, Risk Factors, Odds Ratio, Age of Onset
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.